{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T16:52:02Z","timestamp":1789404722694,"version":"build-2803163510"},"reference-count":77,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2009,12,1]],"date-time":"2009-12-01T00:00:00Z","timestamp":1259625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1016\/j.ctrv.2009.08.002","type":"journal-article","created":{"date-parts":[[2009,9,4]],"date-time":"2009-09-04T11:08:40Z","timestamp":1252062520000},"page":"738-743","source":"Crossref","is-referenced-by-count":9,"title":["Update on the use of erythropoiesis-stimulating agents (ESAs) for the management of anemia of multiple myeloma and lymphoma"],"prefix":"10.1016","volume":"35","author":[{"given":"Eirini","family":"Katodritou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meletios A.","family":"Dimopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Zervas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelos","family":"Terpos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2009.08.002_bib1","first-page":"29","article-title":"Multiple myeloma: review of 869 cases","volume":"50","author":"Kyle","year":"1975","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.ctrv.2009.08.002_bib2","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1159\/000088282","article-title":"Anemia of cancer: impact on patient fatigue and long-term outcome","volume":"69","author":"Harper","year":"2005","journal-title":"Oncology"},{"key":"10.1016\/j.ctrv.2009.08.002_bib3","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1023\/A:1008498705032","article-title":"Frequency and significance of anaemia in non-Hodgkin\u2019s lymphoma patients","volume":"9","author":"Moullet","year":"1998","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2009.08.002_bib4","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1200\/JCO.1995.13.9.2386","article-title":"Randomized phase II comparison of standard CHOP with weekly CHOP in elderly patients with non-Hodgkin\u2019s lymphoma","volume":"13","author":"Meyer","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2009.08.002_bib5","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/j.1600-0609.2006.00739.x","article-title":"Evaluation of anaemia in patients with multiple myeloma and lymphoma: findings of the European Cancer Anaemia Survey","volume":"77","author":"Birgegard","year":"2006","journal-title":"European J Haematol"},{"key":"10.1016\/j.ctrv.2009.08.002_bib6","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3816\/CLM.2003.s.005","article-title":"The implications of anemia in multiple myeloma","volume":"4","author":"Mittelman","year":"2003","journal-title":"Clin Lymphoma"},{"key":"10.1016\/j.ctrv.2009.08.002_bib7","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/sj.thj.6200160","article-title":"Management of disease-related anemia in patients with multiple myeloma or chronic lymphocytic leukemia: epoetin treatment recommendations","volume":"3","author":"Ludwig","year":"2002","journal-title":"Hematol J"},{"key":"10.1016\/j.ctrv.2009.08.002_bib8","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.exphem.2007.01.026","article-title":"Erythropoietin and iron-restricted erythropoiesis","volume":"35","author":"Goodnough","year":"2007","journal-title":"Exp Hematol"},{"key":"10.1016\/j.ctrv.2009.08.002_bib9","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJMra041809","article-title":"Anemia of chronic disease","volume":"352","author":"Weiss","year":"2005","journal-title":"N Eng J Med"},{"key":"10.1016\/j.ctrv.2009.08.002_bib10","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1158\/1078-0432.CCR-07-4153","article-title":"Involvement of hepcidin in the anemia of multiple myeloma","volume":"14","author":"Sharma","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2009.08.002_bib11","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s005990050032","article-title":"The effectiveness and tolerability of of epoietin alfa in patients with multiple myeloma refractory to chemotherapy","volume":"28","author":"Dammacco","year":"1998","journal-title":"Int J Clin Lab Res"},{"key":"10.1016\/j.ctrv.2009.08.002_bib12","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1182\/blood.V87.7.2675.bloodjournal8772675","article-title":"Recombinantv human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin\u2019s lymphoma. A randomized multi-center study","volume":"87","author":"Osterborg","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2009.08.002_bib13","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1093\/jnci\/93.16.1204","article-title":"Epoetin treatment of anemia associated with cancer therapy: a systematic review and meta-analysis of controlled clinical trials","volume":"93","author":"Siedenfeld","year":"2001","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ctrv.2009.08.002_bib14","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1093\/jnci\/djj189","article-title":"Recombinant human erythropoietin in cancer patients: updated meta-analysis of 57 studies including 9353 patients","volume":"98","author":"Bohlius","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ctrv.2009.08.002_bib15","doi-asserted-by":"crossref","first-page":"5960","DOI":"10.1200\/JCO.2005.06.150","article-title":"Maintaining normal hemoglobin levels with epoetin alfa in mainly non-anemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study","volume":"23","author":"Leyland-Jones","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2009.08.002_bib16","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(03)14567-9","article-title":"Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomized, double-blind, placebo-controlled trial","volume":"362","author":"Henke","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2009.08.002_bib17","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1200\/JCO.2006.07.1514","article-title":"Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia","volume":"25","author":"Wright","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2009.08.002_bib18","first-page":"1","article-title":"Danish researchers post long-awaited Aranesp results \u2013 ever so discreetly","volume":"33","author":"Goldberg","year":"2007","journal-title":"Cancer Lett"},{"key":"10.1016\/j.ctrv.2009.08.002_bib19","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1056\/NEJMp078101","article-title":"Weighting the hazards of erythropoiesis stimulation in patients with cancer","volume":"356","author":"Khuri","year":"2007","journal-title":"N Eng J Med"},{"key":"10.1016\/j.ctrv.2009.08.002_bib20","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1200\/JCO.2007.14.3396","article-title":"American Society of Clinical Oncology\/American Society of Hematology 2007. Clinical practice guideline update on the use of epoetin and darbepoetin","volume":"26","author":"Rizzo","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2009.08.002_bib21","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1016\/S0140-6736(09)60502-X","article-title":"Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials","volume":"373","author":"Bohlius","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2009.08.002_bib22","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1200\/JCO.2001.19.11.2865","article-title":"Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized double-blind, placebo-controlled trial","volume":"19","author":"Littlewood","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2009.08.002_bib23","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1365-2141.2005.05440.x","article-title":"Impact of epoetin-b on survival of patients with lymphoproliferative malignancies: long-term follow up of a large randomized study","volume":"12","author":"Osterborg","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ctrv.2009.08.002_bib24","first-page":"108","article-title":"Safety of prophylactic use of darbepoetin alfa in patients with diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP 14 or R-CHOP 21: preliminary results of the LNH03-6B Randomized GELA Study","author":"Delarue","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2009.08.002_bib25","doi-asserted-by":"crossref","first-page":"6941","DOI":"10.1200\/JCO.2005.03.434","article-title":"Darbepoetin alfa for the treatment of chemotherapy-induced anemia: disease progression and survival analysis from four randomized, double-blind, placebo controlled trials","volume":"23","author":"Hedenus","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2009.08.002_bib26","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1200\/JCO.2007.14.2885","article-title":"Darbepoietin alfa for the treatment of anemia in patients with active cancer not receiving chemotherapy nor radiotherapy: results of a phase III multi-center, randomized, double-blind, placebo-controlled study","volume":"26","author":"Smith","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2009.08.002_bib27","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1200\/JCO.2002.08.131","article-title":"Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin beta, in hematological malignancies","volume":"20","author":"\u00d6sterborg","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2009.08.002_bib28","unstructured":"Food and Drug Administration Oncologic Drugs Advisory Committee. http:\/\/www.fda.gov\/obrms\/dockets\/ac\/04\/briefing\/4037b2.htm; 2004 [accessed 05.08]."},{"issue":"suppl. 2","key":"10.1016\/j.ctrv.2009.08.002_bib29","article-title":"A prospectively randomized placeb-controlled trial of epoetin \u2013 a in patients with advanced-stage Hodgkin lymphoma: final analysis of the GHSG HD-15-EPO trial","volume":"94","author":"Engert","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.ctrv.2009.08.002_bib30","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s00277-008-0525-5","article-title":"The use of erythropoiesis stimulating agents in patients with non-myeloid haematological malignancies: a systematic review","volume":"87","author":"Shehata","year":"2008","journal-title":"Ann Hematol"},{"key":"10.1016\/j.ctrv.2009.08.002_bib31","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma","volume":"359","author":"San Miguel","year":"2009","journal-title":"N Eng J Med"},{"key":"10.1016\/j.ctrv.2009.08.002_bib32","article-title":"ESAs do not adversely affect long-term outcomes nor increase the risk for thromboembolic events in multiple myeloma patients treated in the phase III VISTA trial","volume":"b12","author":"Richardson","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2009.08.002_bib33","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1159\/000097464","article-title":"Recombinant human erythropoietin is associated with increased overall survival in patients with multiple myeloma","volume":"117","author":"Baz","year":"2007","journal-title":"Acta Haematol"},{"key":"10.1016\/j.ctrv.2009.08.002_bib34","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/ajh.21239","article-title":"Erythropoiesis stimulating agents are associated with reduced survival in patients with multiple myeloma","volume":"83","author":"Katodritou","year":"2008","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ctrv.2009.08.002_bib35","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/ajh.21270","article-title":"ESAs not the culprit: more studies required","volume":"83","author":"Ludwig","year":"2008","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ctrv.2009.08.002_bib36","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1002\/ajh.21282","article-title":"ESAs: not a convicted felon but still a suspect","volume":"83","author":"Katodritou","year":"2008","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ctrv.2009.08.002_bib37","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1002\/ajh.21244","article-title":"Prospects and perils of retrospective risk assessment of erythropoiesis-stimulating agents","volume":"83","author":"Steensma","year":"2008","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ctrv.2009.08.002_bib38","doi-asserted-by":"crossref","first-page":"35.1","DOI":"10.1146\/annurev.med.60.050307.110718","article-title":"Erythropoietin in cancer patients","volume":"60","author":"Glaspy","year":"2009","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.ctrv.2009.08.002_bib39","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/cncr.22832","article-title":"Expression and function of erythropoietin receptors in tumors","volume":"110","author":"Sinclair","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2009.08.002_bib40","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1002\/cncr.23505","article-title":"Risk factors for leukemic transformation in patients with primary myelofibrosis","volume":"112","author":"Huang","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2009.08.002_bib41","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1182\/blood.V84.4.1056.1056","article-title":"Prediction of response to erythropoietin treatment in chronic anemia of cancer","volume":"84","author":"Ludwig","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2009.08.002_bib42","doi-asserted-by":"crossref","first-page":"4446","DOI":"10.1182\/blood.V86.12.4446.bloodjournal86124446","article-title":"Recombinant human erythropoietin in the anaemia associated with multiple myeloma or non-Hodgkins lymphoma: dose finding and identification of predictors of response","volume":"86","author":"Cazzola","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2009.08.002_bib43","first-page":"434","article-title":"Predictions of response to recombinant human erythropoietin in anemia of malignancy","volume":"81","author":"Cazzola","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.ctrv.2009.08.002_bib44","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1634\/theoncologist.8-1-99","article-title":"Baseline and early treatment factors are not clinically useful for predicting individual response to erythropoietin in anemic cancer patients","volume":"8","author":"Littlewood","year":"2003","journal-title":"Oncologist"},{"key":"10.1016\/j.ctrv.2009.08.002_bib45","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1634\/theoncologist.12-6-748","article-title":"Prediction of responsiveness to treatment with erythropoiesis stimulating factors: a prospective clinical study in patients with solid tumors","volume":"12","author":"Steinmetz","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.ctrv.2009.08.002_bib46","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s00277-007-0258-x","article-title":"Hypochorimic erythrocytes (%): a reliable marker for recognizing iron-restricted erythropoiesis and predicting response to erythropoietin in anemic multiple myeloma and lymphoma patients","volume":"86","author":"Katodritou","year":"2007","journal-title":"Ann Hematol"},{"key":"10.1016\/j.ctrv.2009.08.002_bib47","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1532\/LH96.05030","article-title":"Evaluation of hypochromic erythrocytes in combination with sTfR-F index for predicting response to r-HuEPO in anemic patients with multiple myeloma","volume":"12","author":"Katodritou","year":"2006","journal-title":"Lab Hematol"},{"key":"10.1016\/j.ctrv.2009.08.002_bib48","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1002\/ajh.21448","article-title":"Sequential evaluation of serum hepcidin in anemic myeloma patients: study of correlations with myeloma treatment, disease variables and anemia response","volume":"84","author":"Katodritou","year":"2009","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ctrv.2009.08.002_bib49","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1373\/clinchem.2008.121285","article-title":"Hepcidin as a predictor of response to epoietin in anemic cancer patients","volume":"55","author":"Ukarma","year":"2009","journal-title":"Clin Chem"},{"key":"10.1016\/j.ctrv.2009.08.002_bib50","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.2004.08.119","article-title":"Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy related anemia: a multi-center, open-label, randomized trial","volume":"22","author":"Auerbach","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2009.08.002_bib51","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/sj.leu.2404562","article-title":"Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative disorders","volume":"21","author":"Hedenus","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.ctrv.2009.08.002_bib52","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1200\/JCO.2007.12.2051","article-title":"Randomized trial for intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoietin alfa","volume":"25","author":"Pedrazzoli","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2009.08.002_bib53","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1634\/theoncologist.12-2-231","article-title":"Intravenous ferric gluconate improves response to epoietin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy","volume":"12","author":"Henry","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.ctrv.2009.08.002_bib54","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1200\/JCO.2006.10.4620","article-title":"A randomized multi-center, controlled trial comparing the efficacy and safety of darbepoietin alfa administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia","volume":"25","author":"Bastit","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2009.08.002_bib55","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/ncponc1252","article-title":"Is intravenous iron with erythropoiesis-stimulating agents beneficial in cancer patients with anemia?","volume":"12","author":"Bohlius","year":"2008","journal-title":"Nat Clin Pract Oncol"},{"key":"10.1016\/j.ctrv.2009.08.002_bib56","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2141.2008.07163.x","article-title":"Use of erythropoiesis stimulating agents and intravenous iron for cancer and treatment-related anaemia: the need for predictors and indicators of effectiveness has not abated","volume":"142","author":"Katodritou","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ctrv.2009.08.002_bib57","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/ajh.21189","article-title":"Intravenous iron: a useful therapeutic tool but not a panacea","volume":"83","author":"Katodritou","year":"2008","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ctrv.2009.08.002_bib58","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1080\/10408360091174196","article-title":"Reticulocyte cellular indices: a new approach in the diagnosis of anemias and monitoring of erythropoietic function","volume":"37","author":"Brugnara","year":"2000","journal-title":"Crit Rev Clin Lab Sci"},{"key":"10.1016\/j.ctrv.2009.08.002_bib59","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1001\/jama.299.8.914","article-title":"Venous thromboembolism and mortality associated with recombinant human erythropoietin and darbepoietin administration for the treatment of cancer-related anemia","volume":"299","author":"Bennett","year":"2008","journal-title":"Jama"},{"key":"10.1016\/j.ctrv.2009.08.002_bib60","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/sj.bjc.6604408","article-title":"Effect of treatment with epoietin beta on survival, tumor progression and thromboembolic events in patients with cancer: an up-dated meta-analysis of 12 randomised controlledstidies including 2301 patients","volume":"99","author":"Aapro","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2009.08.002_bib61","unstructured":"Agency of Healthcare Research and Quality. Comparative effectiveness of of epoietin and darbepoietin for managing anemia in patients undergoing cancer treatment. http:\/\/effectivehealthcare.ahrq.gov\/>;.2006. [accessed 23.05.06]."},{"key":"10.1016\/j.ctrv.2009.08.002_bib62","unstructured":"Background Information of Oncologic Drugs Advisory Committee Meeting. Information package 55;. <http:\/\/www.fda.gov>."},{"key":"10.1016\/j.ctrv.2009.08.002_bib63","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1634\/theoncologist.13-S3-11","article-title":"Venous thromboembolic events and erythropoiesis-stimulating agents: an update","volume":"13","author":"Dicato","year":"2008","journal-title":"Oncologist"},{"key":"10.1016\/j.ctrv.2009.08.002_bib64","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1525-139X.2008.00435.x","article-title":"Thrombosis with erythropoiesis stimulating agents \u2013 does iron-deficient erythropoiesis play a role?","volume":"21","author":"Dahl","year":"2008","journal-title":"Sem Dial"},{"key":"10.1016\/j.ctrv.2009.08.002_bib65","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1002\/cncr.21496","article-title":"Risk factors for chemotherapy-associated venous thrombormbolism in a prospective observational study","volume":"104","author":"Khorana","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2009.08.002_bib66","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00277-007-0416-1","article-title":"Iron and thrombosis","volume":"87","author":"Franchini","year":"2008","journal-title":"Ann Hematol"},{"key":"10.1016\/j.ctrv.2009.08.002_bib67","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1200\/JCO.2001.19.11.2865","article-title":"Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving non-platinum chemotherapy. Results of a randomized, double-blind, placebo-controlled trial","volume":"19","author":"Littlewood","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2009.08.002_bib68","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1111\/j.1445-5994.2008.01736.x","article-title":"Outcomes and predicting response in anaemic chemotherapy patients treated with epoetin alfa. A multicentre, 4-month, open-label study in Australia and New Zealand","volume":"38","author":"Bell","year":"2008","journal-title":"Intern Med J"},{"key":"10.1016\/j.ctrv.2009.08.002_bib69","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1046\/j.1365-2141.2001.02715.x","article-title":"Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma","volume":"113","author":"Dammacco","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ctrv.2009.08.002_bib70","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1046\/j.1365-2141.2003.04448.x","article-title":"Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study","volume":"122","author":"Hedenus","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ctrv.2009.08.002_bib71","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1002\/cncr.22221","article-title":"Quality of life and health benefits early treatment of mild anemia","volume":"107","author":"Straus","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2009.08.002_bib72","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1007\/BF00540022","article-title":"Guidelines for reporting results of quality of life assessment in clinical trials","volume":"5","author":"Staquet","year":"1996","journal-title":"Qual Life Res"},{"key":"10.1016\/j.ctrv.2009.08.002_bib73","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1080\/02841860701744498","article-title":"The cost-effectiveness of treatment with erythropoietin compared to red blood cell transfusions for patients with chemotherapy induced anaemia: a Markov model","volume":"47","author":"Borg","year":"2008","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ctrv.2009.08.002_bib74","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.ctrv.2006.04.007","article-title":"European guidelines for the management of chemotherapy induced anaemia and health economic aspects of treatment","volume":"32","author":"Repetto","year":"2006","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ctrv.2009.08.002_bib75","first-page":"1","article-title":"A systematic review and economic evaluation of epoetin alpha, epoetin beta and darbepoetin alpha in anaemia associated with cancer, especially that attributable to cancer treatment","volume":"13","author":"Wilson","year":"2007","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.ctrv.2009.08.002_bib76","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2165\/00019053-200826020-00002","article-title":"Management of anaemia: a critical and systematic review of the cost effectiveness of erythropoiesis-stimulating agents","volume":"26","author":"Duh","year":"2008","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.ctrv.2009.08.002_bib77","first-page":"459","article-title":"Practice and costs of red blood cell (RBC) transfusion in an oncological unit","volume":"28","author":"Norum","year":"2008","journal-title":"Anticancer Res"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737209001170?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737209001170?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T01:00:57Z","timestamp":1590109257000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737209001170"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12]]},"references-count":77,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["S0305737209001170"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2009.08.002","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2009,12]]}}}